Form 4: GeneDx CFO Kevin Feeley Executes RSU Vesting and Tax Sale

GeneDx Holdings Corp. CFO Kevin Feeley acquired 754 shares via RSU vesting and sold 392 shares to cover tax obligations.

Summary

• CFO Kevin Feeley acquired 754 shares of Class A Common Stock on April 29, 2026, through the vesting of Restricted Stock Units (RSUs).
• The reporting person sold 392 shares at a weighted average price of $65.1926 to satisfy mandatory tax withholding obligations.
• Following these transactions, the CFO holds 34,942 shares of Class A Common Stock directly.
• The CFO retains additional unvested equity, including 92,419 RSUs and options to purchase 25,906 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was purely administrative and non-discretionary in nature.

Positives

• The transaction reflects the standard vesting of equity compensation, indicating ongoing alignment between executive interests and shareholder value.

Negatives

• None; the sale was a non-discretionary 'sell to cover' transaction specifically for tax purposes.

Risks

• Continued reliance on equity-based compensation and the potential for future tax-related sales.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a routine disclosure of insider equity transactions.

Industry Context

StockSavvy.ai notes that routine RSU vesting and 'sell-to-cover' transactions by C-suite executives are standard corporate governance practices and generally do not signal a change in management sentiment regarding the company's long-term prospects.

Comparison to Industry Standards

• The transaction follows standard industry practices for executive compensation and tax compliance.
• The 'sell-to-cover' mechanism is a common method used by executives across the biotech and healthcare sectors to manage tax liabilities associated with equity awards.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine tax-related sale.

Next Steps

• Future vesting of remaining 92,419 RSUs and 25,906 options according to their respective schedules.

Key Dates

Keywords

GeneDx, WGS, Insider Trading, Form 4, CFO, Equity Compensation, RSU